Literature DB >> 15846378

BCR/ABL, mRNA translation and apoptosis.

D Perrotti, F Turturro, P Neviani.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15846378     DOI： 10.1038/sj.cdd.4401606

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN： 1350-9047            Impact factor:   15.828


× No keyword cloud information.
  11 in total

1.  A MAPK/HNRPK pathway controls BCR/ABL oncogenic potential by regulating MYC mRNA translation.

Authors:  Mario Notari; Paolo Neviani; Ramasamy Santhanam; Bradley W Blaser; Ji-Suk Chang; Annamaria Galietta; Anne E Willis; Denis C Roy; Michael A Caligiuri; Guido Marcucci; Danilo Perrotti
Journal:  Blood       Date:  2005-11-17       Impact factor: 22.113

Review 2.  BCR-ABL1 kinase-dependent alteration of mRNA metabolism: potential alternatives for therapeutic intervention.

Authors:  Danilo Perrotti; Jason G Harb
Journal:  Leuk Lymphoma       Date:  2011-01-11

3.  High levels of the BCR/ABL oncoprotein are required for the MAPK-hnRNP-E2 dependent suppression of C/EBPalpha-driven myeloid differentiation.

Authors:  Ji Suk Chang; Ramasamy Santhanam; Rossana Trotta; Paolo Neviani; Anna M Eiring; Edward Briercheck; Mattia Ronchetti; Denis C Roy; Bruno Calabretta; Michael A Caligiuri; Danilo Perrotti
Journal:  Blood       Date:  2007-05-02       Impact factor: 22.113

4.  Role of BCR-ABL-Y177-mediated p27kip1 phosphorylation and cytoplasmic localization in enhanced proliferation of chronic myeloid leukemia progenitors.

Authors:  S Chu; T McDonald; R Bhatia
Journal:  Leukemia       Date:  2010-03-04       Impact factor: 11.528

5.  Inhibition of polysome assembly enhances imatinib activity against chronic myelogenous leukemia and overcomes imatinib resistance.

Authors:  Min Zhang; Wuxia Fu; Sharmila Prabhu; James C Moore; Je Ko; Jung Woo Kim; Brian J Druker; Valerie Trapp; John Fruehauf; Hermann Gram; Hung Y Fan; S Tiong Ong
Journal:  Mol Cell Biol       Date:  2008-08-11       Impact factor: 4.272

6.  The role of translation initiation regulation in haematopoiesis.

Authors:  Godfrey Grech; Marieke von Lindern
Journal:  Comp Funct Genomics       Date:  2012-05-09

Review 7.  ReSETting PP2A tumour suppressor activity in blast crisis and imatinib-resistant chronic myelogenous leukaemia.

Authors:  D Perrotti; P Neviani
Journal:  Br J Cancer       Date:  2006-09-05       Impact factor: 7.640

8.  A novel Bcr-Abl-mTOR-eIF4A axis regulates IRES-mediated translation of LEF-1.

Authors:  Becky Pinjou Tsai; Judith Jimenez; Sharon Lim; Kerry D Fitzgerald; Min Zhang; Charles T H Chuah; Haley Axelrod; Luke Wilson; S Tiong Ong; Bert L Semler; Marian L Waterman
Journal:  Open Biol       Date:  2014-11       Impact factor: 6.411

Review 9.  Mechanisms of Disease Progression and Resistance to Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia: An Update.

Authors:  Luana Bavaro; Margherita Martelli; Michele Cavo; Simona Soverini
Journal:  Int J Mol Sci       Date:  2019-12-05       Impact factor: 5.923

Review 10.  The Role of N6-Methyladenosine (m6A) Methylation Modifications in Hematological Malignancies.

Authors:  Yan Zhao; Hongling Peng
Journal:  Cancers (Basel)       Date:  2022-01-11       Impact factor: 6.639
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.